These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effect of thrombotic and antithrombotic drugs on the surface charge characteristics of canine blood vessels: in vivo and in vitro studies. Srinivasan S; Aaron R; Chopra PS; Lucas T; Sawyer PN Surgery; 1968 Oct; 64(4):827-33. PubMed ID: 5683809 [No Abstract] [Full Text] [Related]
5. [Heparin in surgery and artificial circulation: pro and contra. Is there an alternative?]. Roĭtman EV; Dement'eva II; Meshcheriakov AV Anesteziol Reanimatol; 1997; (6):65-9. PubMed ID: 9511253 [No Abstract] [Full Text] [Related]
6. Activation of coagulation by heparin-protamine complexes as demonstrated by thrombotest. Godal HC; Gjengedal G Scand J Haematol; 1971; 8(3):194-9. PubMed ID: 5093996 [No Abstract] [Full Text] [Related]
7. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Poterucha TJ; Libby P; Goldhaber SZ Thromb Haemost; 2017 Feb; 117(3):437-444. PubMed ID: 27975101 [TBL] [Abstract][Full Text] [Related]
8. [Protamine complexes with antithrombin III and heparin]. Roszkowska W; Worowski K Acta Haematol Pol; 1982; 13(1-2):25-8. PubMed ID: 7180353 [No Abstract] [Full Text] [Related]
10. Studies on the anticoagulant action of heparin, protamine, and Polybrene in the activation of factor IX. Shanberge JN; Fukui H J Lab Clin Med; 1967 Jun; 69(6):927-37. PubMed ID: 6025496 [No Abstract] [Full Text] [Related]
11. Interaction studies with metolazone, heparin and protamine sulfate. Yelnosky J; Borrelli A; Kaiser F; Belair E Arch Int Pharmacodyn Ther; 1973 Jul; 204(1):5-11. PubMed ID: 4746632 [No Abstract] [Full Text] [Related]
12. [Principles of the treatment of hypercoagulabilities with a rational anticoagulant therapy]. Raby C Presse Med (1893); 1969 Jan; 77(1):17-9. PubMed ID: 5785756 [No Abstract] [Full Text] [Related]
14. [Changes in the adhesiveness of thrombocytes under the effect of anticoagulants]. Merkulov MF; Lakin KM; Fel'dbaum VA; Efimov VS Farmakol Toksikol; 1968; 31(6):706-9. PubMed ID: 5713582 [No Abstract] [Full Text] [Related]
15. [Effect of regulating blood clotting with heparin and its antagonists on mast cells]. Efimov VS; Rozkin MIa; Poberiĭ IA; Lindner DP Farmakol Toksikol; 1981; 44(1):80-5. PubMed ID: 7262304 [TBL] [Abstract][Full Text] [Related]
16. [Clinical use of heparin-heparinoid-mixtures]. Hörder MH; Stier WD; Brunswig D Arzneimittelforschung; 1969 Nov; 19(11):1873-6. PubMed ID: 4190000 [No Abstract] [Full Text] [Related]
17. [Experimental study of the heparin antagonist protamine chloride]. Efimov VS Farmakol Toksikol; 1968; 31(5):601-4. PubMed ID: 5707736 [No Abstract] [Full Text] [Related]
18. Advances in Heparins and Related Research. An Epilogue. Fareed J; Bacher P; Jeske W Molecules; 2018 Feb; 23(2):. PubMed ID: 29439508 [TBL] [Abstract][Full Text] [Related]
19. [Interaction of the calcium salt of heparin with specific antagonists and ethacizine]. Ushkalova EA; Petrov AD; Kremneva VF; Shcheglova NV Farmakol Toksikol; 1988; 51(6):53-6. PubMed ID: 3234542 [TBL] [Abstract][Full Text] [Related]
20. Heparin coupled to albumin, dextran and ficoll: influence on blood coagulation and platelets, and in vivo duration. Teien AN; Odegård R; Christensen TB Thromb Res; 1975 Aug; 7(2):273-84. PubMed ID: 1162648 [No Abstract] [Full Text] [Related] [Next] [New Search]